跳至主要内容
临床试验/NCT01485666
NCT01485666已完成不适用

Reduce Driveline Trauma Through Stabilization and Exit Site Management (RESIST) Pilot Study Protocol

Abbott Medical Devices5 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
5
主要终点
Demonstration of the wearability and usability of the Percutaneous Lead Management Kit

研究概览

简要总结

The purpose of this study is to evaluate the feasibility of a Percutaneous Lead Management Kit for HeartMate II driveline stabilization and exit site management.

详细描述

The Percutaneous Lead Management Kit is a combination of commercially available components that are packaged together in a kit to be used for HeartMate II driveline exit site cleaning, dressing and stabilization. The RESIST study is a prospective, non-randomized study to evaluate the wearability and usability of the Percutaneous Lead Management Kit. Evaluation of the Percutaneous Lead Management Kit for wearability and usability will be performed for 30 days from enrollment. Study patients will also be followed for up to 6 months for any evidence of driveline infection.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent form
  • 16 years of age or older
  • Supported by HeartMate II LVAD continuously for at least 6 months and not currently hospitalized
  • Will continue on LVAD support for at least another 30 days
  • No driveline or systemic infection
  • Willing and able to perform kit dressing changes at least once every 7 days for 30 days
  • Can fill out study forms
  • Can use a digital camera
  • Willing to return to clinic for final study visit in 30 days

排除标准

  • High risk for non-compliance
  • Ongoing mechanical circulatory support other than HeartMate II LVAD
  • Sensitivity to kit components
  • Skin condition that may react to kit component adhesives
  • Already using all components of Percutaneous Lead Management Kit

结局指标

主要结局

Demonstration of the wearability and usability of the Percutaneous Lead Management Kit

时间窗: Up to 30 days

次要结局

  • Durability of the Percutaneous Lead Management Kit's infection mitigation and stabilization(Up to 7 days continuous kit use)
  • Incidence of adverse reactions to any Percutaneous Lead Management Kit components(Up to 6 months)
  • Evidence of driveline infection(Up to 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验